- Article
- Source: Campus Sanofi
Prescribing Information Update for Severe Asthma Biologic
Prescribing information for biologic therapies is periodically updated to reflect new clinical trial data, expanded indications or refined safety guidance. This page summarises a recent update relevant to a biologic used in the management of severe asthma with a Type 2 inflammatory phenotype. Healthcare professionals prescribing or considering this therapy should review the updated information to ensure current practice aligns with the latest approved guidance. Full details should always be confirmed against the current approved package insert.
Label updates typically reflect new clinical trial data, expanded or refined indications, or updated safety and monitoring guidance based on accumulated real-world evidence. Regulatory review processes ensure that prescribing information remains aligned with the current understanding of a therapy's benefit-risk profile. Staying current with label updates helps ensure prescribing practice reflects the latest approved guidance. This is particularly relevant for biologics used in evolving treatment landscapes such as severe asthma.
Healthcare professionals should review the updated prescribing information in full to understand any changes relevant to patient selection, dosing or monitoring. Existing patients on therapy should be assessed against any updated criteria where relevant. Any significant changes should be incorporated into ongoing patient discussions and treatment planning. The current approved package insert remains the definitive reference for prescribing decisions.
The current approved prescribing information is available through the official package insert associated with the product's registration in South Africa. This platform provides supporting clinical context but does not replace the formal prescribing document. Healthcare professionals should confirm they are referencing the most recent version when making prescribing decisions. Any discrepancies should be resolved by referring to the official regulatory-approved documentation.
Confirm that you are a healthcare professional to continue reading.
Click login to continue
The cascade of Type 2 Inflammation: How do asthma biologic therapies work?
In the era of targeted biologic therapies and precision medicine, guided by biomarkers — how do you know which biologic is right for which patient?
Type 2 inflammation in paediatric asthma
This distinguished presentation by Prof Charl Verwey from the Division of Paediatric Pulmonology at the University of the Witwatersrand and Chris Hani Baragwanath Academic Hospital offers an evidence-based exploration of Type 2 inflammation in paediatric asthma management.
